"The US market is PolyNovo’s single largest market and in the past year we have established many key hospital accounts. Surgeons continue to be impressed with the robust nature of NovoSorb BTM and the ability to utilise it for indications that they normally would not use a dermal matrix/scaffold. "
Is Polynovo expanding the market with Novsorb BTM?
Was their previous estimates of the addressable market based on BTM simply superseding competitors, or did they factor in other uses and an expansion of the market?
It's early days but this sounds very very promising.
Ann: Annual Report FY19 and 4E, page-31
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
-0.040(1.94%) |
Mkt cap ! $1.395B | |||
| Open | High | Low | Value | Volume |
| $2.01 | $2.04 | $2.00 | $1.537M | 762.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41008 | $2.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 5942 | 2 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |